# ScoreItem: Trofismo Urogenital

**ID:** `019bf31d-2ef0-7e31-b393-f2783549d874`
**FullName:** Trofismo Urogenital (Histórico de doenças - Histórico de saúde (Questionar ativamente sobre doenças/sintomas - passado ou atual): - Genitália feminina)

**Preparation Metadata:**
- Quality Grade: **EXCELLENT**
- Total Chunks: 30 de 2 artigos
- Avg Similarity: 0.696

---

## Contexto

Você é um especialista em medicina funcional integrativa e está contribuindo com o **Escore Plenya** — um escore completo de análise de saúde que avalia todos os aspectos da saúde, performance e longevidade humana. Cada ScoreItem representa um parâmetro clínico, laboratorial, genético, comportamental ou histórico que compõe esse escore.

Seu papel é gerar conteúdo clínico de alta qualidade para enriquecer cada parâmetro do escore com relevância clínica, orientação ao paciente e conduta prática.

**Regras inegociáveis:**
- Use **apenas** o conhecimento médico real consolidado e os dados presentes nos chunks científicos abaixo
- **Não alucine, não invente** dados, estudos, estatísticas ou referências que não estejam nos chunks ou no seu conhecimento médico estabelecido
- Se um dado específico não constar nos chunks e não for do seu conhecimento consolidado, **não o inclua**
- Seja preciso: prefira omitir a inventar

## Instrução

Com base nos chunks científicos abaixo, gere as respostas em formato JSON.

**O JSON deve obrigatoriamente conter o campo `score_item_id` com o valor `019bf31d-2ef0-7e31-b393-f2783549d874`.**

```json
{
  "score_item_id": "019bf31d-2ef0-7e31-b393-f2783549d874",
  "clinical_relevance": "Texto técnico para médicos (1000-5000 chars): definição fisiológica precisa, valores de referência e interpretação, fisiopatologia resumida, dados epidemiológicos com números concretos, estratificação de risco baseada em evidências.",
  "points": 1,
  "patient_explanation": "Texto simples para pacientes (500-1000 chars): o que é este parâmetro sem jargões, por que é importante para a saúde, o que valores alterados podem significar. Tom tranquilizador e educativo.",
  "conduct": "Conduta clínica em Markdown (1000-5000 chars): investigação complementar necessária, critérios de encaminhamento a especialistas, intervenções baseadas em evidências. Use bullet points, seções e negrito."
}
```

**Regras para `points` (1-50):**
- Baixo impacto clínico: 1-9 pts
- Alto impacto clínico: 10-19 pts
- Alto impacto em mortalidade: 20-50 pts
- Critérios: gravidade/mortalidade (40%), prevalência (30%), intervencionabilidade (30%)

---

### Contexto Científico

**ScoreItem:** Trofismo Urogenital (Histórico de doenças - Histórico de saúde (Questionar ativamente sobre doenças/sintomas - passado ou atual): - Genitália feminina)

**30 chunks de 2 artigos (avg similarity: 0.696)**

### Chunk 1/30
**Article:** Study of Vulvovaginal Atrophy and Genitourinary Syndrome of Menopause and Its Impact on the Quality of Life of Postmenopausal Women in Central India (2024)
**Journal:** Cureus
**Section:** results | **Similarity:** 0.784

the Study of Women's Sexual Health and the North American Menopause
Society
. Menopause. 2014, 21:1063-8. 
10.1097/GME.0000000000000329
3
. 
Weber MA, Limpens J, Roovers JP: 
Assessment of vaginal atrophy: a review
. Int Urogynecol J. 2015, 26:15-
28. 
10.1007/s00192-014-2464-0
4
. 
Palacios S, Nappi RE, Bruyniks N, Particco M, Panay N: 
The European Vulvovaginal Epidemiological Survey
(EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause
. Climacteric. 2018,
21:286-91. 
10.1080/13697137.2018.1446930
5
. 
Moral E, Delgado JL, Carmona F, et al.: 
The impact of genitourinary syndrome of menopause on well-being,
functioning, and quality of life in postmenopausal women
. Menopause. 2018, 25:1418-23.
10.1097/GME.0000000000001148
6
. 
Palma F, Volpe A, Villa P, Cagnacci A: 
Vaginal atrophy of women in postmenopause. Results from a
multicentric observational study: The AGATA study
. Maturitas. 2016, 83:40-4.
2024 Ulhe et al. Cureus 16(2): e54802.

---

### Chunk 2/30
**Article:** Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women (2019)
**Journal:** Front Endocrinol (Lausanne)
**Section:** results | **Similarity:** 0.766

Urogenitalageing:anoldproblemnewlyrecognized.Maturitas.(1995)22(Suppl.1):S15.doi:10.1016/0378-5122(95)00956-634.PalmaF,XholliA,CagnacciA,astheWritingGroupoftheAGATAStudy.Themostbothersomesymptomofvaginalatrophy:evidence
fromtheobservationalAGATAstudy.Maturitas.(2018)108:1823.doi:10.1016/j.maturitas.2017.11.00735.PalmaF,VolpeA,VillaP,CagnacciA,WritingGroupofGATAStudy.VaginalAtrophyofWomeninPostmenopause.Resultsfroma
multicentricobservationalstudy:theAGATAstudy.Maturitas.(2016)83:404.doi:10.1016/j.maturitas.2015.09.00136.KingsbergSA,KrychmanM,GrahamS,BernickB,MirkinS.Thewomen’sEMPOWERsurvey:identifyingwomen’sperceptionsonvulvarandvaginalatrophyanditstreatment.JSexMed.(2017)14:41324.doi:10.1016/j.jsxm.2017.01.01037.KingsbergSA,LarkinL,KrychmanM,ParishSJ,BernickB,MirkinS.WISDOMsurvey:attitudesandbehaviorsofphysicianstowardvulvarandvaginalatrophy(VVA)treatmentinwomenincluding
thosewithbreastcancerhistory.Menopause.(2019)26:12431.doi:10.1097/GME.000000000000119438.KingsbergSA,S

---

### Chunk 3/30
**Article:** Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women (2019)
**Journal:** Front Endocrinol (Lausanne)
**Section:** results | **Similarity:** 0.751

A,Kokot-KierepaM,GoldsteinJ,NappiRE.VaginalhealthintheUnitedStates:resultsfromthevaginalhealth:
insights,views&attitudessurvey.Menopause.(2013)20:10438.doi:10.1097/GME.0b013e318287342d95.NappiRE,KrychmanML.TheAmerican-Europeandiﬀerenceinvulvarandvaginalatrophyviews:alessonfromtheREVIVESurvey.Climacteric.(2016)19:2525.doi:10.3109/13697137.2016.117302696.PastoreLM,CarterRA,HulkaBS,WellsE.Self-reportedurogenitalsymptomsinpostmenopausalwomen:Women’sHealthInitiative.Maturitas.(2004)49:292303.doi:10.1016/j.maturitas.2004.06.01997.GassM,LarsonJ,CochraneB,MansonJE,LaneD,BarnabeiV,etal.SexualactivityandvaginalsymptomsinthepostinterventionphaseoftheWomen’sHealthInitiativeHormoneTherapyTrials.Menopause.(2018)25:25264.doi:10.1097/GME.000000000000099498.Castelo-BrancoC,BigliaN,NappiRE,SchwenkhagenA,PalaciosS.Characteristicsofpost-menopausalwomenwithgenitourinarysyndromeofmenopause:implicationsforvulvovaginalatrophydiagnosisand
treatmentselection.Maturitas.(2015)81:4629.doi:10.1016/j

---

### Chunk 4/30
**Article:** Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women (2019)
**Journal:** Front Endocrinol (Lausanne)
**Section:** methods | **Similarity:** 0.727

A.Long-termnon-hormonaltreatmentofvaginaldryness.ClinPractSexuality.(1992)8:38.69.PanayN.Genitourinarysyndromeofthemenopausedawnofanewera?Climacteric.(2015)18(Suppl.1):137.doi:10.3109/13697137.2015.107056470.GoldsteinI.Recognizingandtreatingurogenitalatrophyinpostmenopausalwomen.JWomensHealth.(2010)19:42532.doi:10.1089/jwh.2009.138471.NilssonK,RisbergB,HeimerG.Thevaginalepitheliuminthepostmenopausecytology,histologyandpHasmethodsofassessment.

---

### Chunk 5/30
**Article:** Study of Vulvovaginal Atrophy and Genitourinary Syndrome of Menopause and Its Impact on the Quality of Life of Postmenopausal Women in Central India (2024)
**Journal:** Cureus
**Section:** results | **Similarity:** 0.718

: 
Vaginal atrophy of women in postmenopause. Results from a
multicentric observational study: The AGATA study
. Maturitas. 2016, 83:40-4.
2024 Ulhe et al. Cureus 16(2): e54802. DOI 10.7759/cureus.54802
18
 of 
19

10.1016/j.maturitas.2015.09.001
7
. 
Chua Y, Limpaphayom KK, Cheng B, Ho C M, Sumapradja K, Altomare C, Huang K: 
Genitourinary syndrome
of menopause in five asian countries: results from the pan-asian REVIVE survey
. Climacteric. 2017, 20:367-
73.
8
. 
Nappi RE, Palacios S, Bruyniks N, Particco M, Panay N, EVES Study investigators: 
The burden of
vulvovaginal atrophy on women’s daily living: implications on quality of life from a face-to-face real-life
survey
. Menopause. 2019, 26:485-91.
9
. 
Cumming GP, Herald J, Moncur R, Currie H, Lee AJ: 
Women's attitudes to hormone replacement therapy,
alternative therapy and sexual health: a web-based survey
. Menopause Int. 2007, 13:79-83.
10.1258/175404507780796424
10
.

---

### Chunk 6/30
**Article:** Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women (2019)
**Journal:** Front Endocrinol (Lausanne)
**Section:** other | **Similarity:** 0.713

aturitas.2012.06.009113.NAMS.(2013).Managementofsymptomaticvulvovaginalatrophy:2013positionstatementofTheNorthAmericanMenopauseSociety.Menopause.20,888-902;quiz903-4.doi:10.1097/GME.0b013e3182a122c2114.BruyniksN,NappiRE,Castelo-BrancoC,deVilliersTJ,SimonJ.Eﬀectofospemifeneonmoderateorseveresymptomsofvulvarand
vaginalatrophy.Climacteric.(2016)19:605.doi:10.3109/13697137.2015.1113517115.EdwardsD,PanayN.Treatingvulvovaginalatrophy/genitourinarysyndromeofmenopause:howimportantisvaginallubricant
andmoisturizercomposition?Climacteric.(2016)19:15161.doi:10.3109/13697137.2015.1124259116.MercierJ,MorinM,ZakiD,ReichetzerB,LemieuxMC,KhaliféS,etal.Pelvicﬂoormuscletrainingasatreatmentforgenitourinarysyndrome
ofmenopause:asingle-armfeasibilitystudy.Maturitas.(2019)125:5762.doi:10.1016/j.maturitas.2019.03.002
FrontiersinEndocrinology|www.frontiersin.org10August2019|Volume10|Article561

Nappietal.VaginalHealthandAging
117.TadirY,GasparA,Lev-SagieA,AlexiadesM,AlinsodR,BaderA,etal.Lightandene

---

### Chunk 7/30
**Article:** Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women (2019)
**Journal:** Front Endocrinol (Lausanne)
**Section:** other | **Similarity:** 0.711

12)9:64151;quiz652.doi:10.1111/j.1743-6109.2012.02649.x121.BassonR,SchultzWW.Sexualsequelaeofgeneralmedicaldisorders.Lancet.(2007)369:40924.doi:10.1016/S0140-6736(07)60197-4122.ConstantineGD,BruyniksN,PrincicN,HuseD,PalmerL,LenhartG,etal.Incidenceofgenitourinaryconditionsinwomenwitha
diagnosisofvulvar/vaginalatrophy.CurrMedResOpin.(2014)30:1438.doi:10.1185/03007995.2013.850068123.PhillipsNA,BachmannGA.Genitourinarysyndromeofmenopause:commonproblem,eﬀectivetreatments.CleveClinJMed.(2018)85:3908.doi:10.3949/ccjm.85a.15081ConﬂictofInterestStatement:Duringthepast2years,RNhadaﬁnancialrelationship(lecturer,memberofadvisoryboardsand/orconsultant)withBayerHealthCare,Endoceutics,Exceltis,GedeonRichter,MSD,NovoNordisk,Palatin,Pﬁzer,Shionogi,Teva,andTheramex.Thesecompanieshavenoinvolvementwiththestudy.
Theremainingauthorsdeclarethattheresearchwasconductedintheabsenceofanycommercialorﬁnancialrelationshipsthatcouldbeconstruedasapotentialconﬂictofinterest.

---

### Chunk 8/30
**Article:** Study of Vulvovaginal Atrophy and Genitourinary Syndrome of Menopause and Its Impact on the Quality of Life of Postmenopausal Women in Central India (2024)
**Journal:** Cureus
**Section:** results | **Similarity:** 0.708

women with
self-reported distressing sexual problems
. J Womens Health (Larchmt). 2009, 18:461-8.
10.1089/jwh.2008.1133
20
. 
Nappi RE, Kokot-Kierepa M: 
Vaginal health: insights, views & attitudes (VIVA) - results from an
international survey
. Climacteric. 2012, 15:36-44. 
10.3109/13697137.2011.647840
21
. 
Nappi RE, Kokot-Kierepa M: 
Women's voices in the menopause: results from an international survey on
vaginal atrophy
. Maturitas. 2010, 67:233-8. 
10.1016/j.maturitas.2010.08.001
22
. 
The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007
position statement of The North American Menopause Society
. Menopause. 2007, 14:355-69.
10.1097/gme.0b013e31805170eb
23
. 
Bygdeman M, Swahn ML: 
Replens versus dienoestrol cream in the symptomatic treatment of vaginal
atrophy in postmenopausal women
. Maturitas. 1996, 23:259-63. 
10.1016/0378-5122(95)00955-8
24
.

---

### Chunk 9/30
**Article:** Study of Vulvovaginal Atrophy and Genitourinary Syndrome of Menopause and Its Impact on the Quality of Life of Postmenopausal Women in Central India (2024)
**Journal:** Cureus
**Section:** other | **Similarity:** 0.704

Gynecol
Endocrinol. 2016, 32:602-6. 
10.1080/09513590.2016.1183627
27
. 
Huang AJ, Gregorich SE, Kuppermann M, et al.: 
Day-to-day impact of vaginal aging questionnaire: a
multidimensional measure of the impact of vaginal symptoms on functioning and well-being in
postmenopausal women
. Menopause. 2015, 22:144-54. 
10.1097/GME.0000000000000281
28
. 
Nappi RE, Palacios S, Panay N, Particco M, Krychman ML: 
Vulvar and vaginal atrophy in four European
countries: evidence from the European REVIVE Survey
. Climacteric. 2016, 19:188-97.
10.3109/13697137.2015.1107039
29
. 
Angelou K, Grigoriadis T, Diakosavvas M, Zacharakis D, Athanasiou S: 
The genitourinary syndrome of
menopause: an overview of the recent data
. Cureus. 2020, 12:e7586. 
10.7759/cureus.7586
30
. 
Ojha N, Bista KD, Bajracharya S, Katuwal N: 
Genitourinary syndrome of menopause among postmenopausal
women in a tertiary care centre: a descriptive cross-sectional study
. JNMA J Nepal Med Assoc. 2022, 60:126-
31.
2024 Ulhe et al.

---

### Chunk 10/30
**Article:** Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women (2019)
**Journal:** Front Endocrinol (Lausanne)
**Section:** results | **Similarity:** 0.699

ducts.
Lubricantsareshort-actingsubstances(water-,silicone-,oroil-based)whichareusefultoreducefrictionduringsexualactivity,whereasmoisturizersarelongeractingthanlubricantsand
mayexertatrophiceﬀect(
115
).Pelvicﬂoormuscletraining(PFMT)programinpostmenopausalwomenwithurinary
incontinenceisfeasibleandimprovesVVA/GSMsymptoms
andsigns,aswellasdisplaysapositiveimpactonactivities
ofdailyliving,QoLandsexualfunction(
116
).MicroablativefractionalCO2laser,thenon-ablativevaginalErbiumYAGlaser(VEL)andenergy-baseddevicesareincreasinglyusedtoalleviateVVA/GSMsymptomswithpromisingresultsandagoodsafety
proﬁle(
117
).VVA/GSMASANEGATIVEMARKEROF
WOMEN’SAGING:ISTHEREENOUGH
EVIDENCE?

---

### Chunk 11/30
**Article:** Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women (2019)
**Journal:** Front Endocrinol (Lausanne)
**Section:** other | **Similarity:** 0.691

rophy
(VVA)/GenitourinarySyndromeof
Menopause(GSM)forHealthyAging
inWomen
RossellaE.Nappi1,2*,EllisMartini1,LauraCucinella1,2,SilviaMartella1,2,LaraTiranini1,2,AlessandraInzoli1,2,EmanuelaBrambilla1,2,DavidBosoni1,2,ChiaraCassani3andBarbaraGardella2,31ResearchCenterforReproductiveMedicine,GynecologicalEndocrinologyandMenopause,UniversityofPavia,Pavia,Italy,2DepartmentofClinical,Surgical,DiagnosticandPediatricSciences,UniversityofPavia,Pavia,Italy,3ObstetricsandGynecologyUnit,IRCCSSanMatteoFoundation,UniversityofPavia,Pavia,ItalyVaginalhealthisanessentialcomponentofactiveandhealthyaginginwomenatmidlifeandbeyond.Asaconsequenceofhormonaldeprivationandsenescence,theanatomyandfunctionofurogenitaltissuesaresigniﬁcantlyaffectedandvulvovaginalatrophy(VVA)mayoccur.Inahighproportionofpostmenopausalwomen,progressiveandchronicVVAsymptomshaveastrongimpactonsexualfunctionandqualityoflife.Thenewdeﬁnitionofgenitourinarysyndromeofmenopause(GSM)comprisesgenitalsymptoms(dryness,burning,itching,irrita

---

### Chunk 12/30
**Article:** Study of Vulvovaginal Atrophy and Genitourinary Syndrome of Menopause and Its Impact on the Quality of Life of Postmenopausal Women in Central India (2024)
**Journal:** Cureus
**Section:** introduction | **Similarity:** 0.690

cology
Keywords:
 quality of life, vaginal dryness, women’s health, genitourinary syndrome, vulvovaginal atrophy,
postmenopausal woman
Introduction
Urogenital health is an essential element of postmenopausal females and their partners' healthy aging. One
1
1
1
1
 
Open Access Original
Article
 
DOI:
 10.7759/cureus.54802
How to cite this article
Ulhe S C, Acharya N, Vats A, et al. (February 24, 2024) Study of Vulvovaginal Atrophy and Genitourinary Syndrome of Menopause and Its Impact
on the Quality of Life of Postmenopausal Women in Central India. Cureus 16(2): e54802. 
DOI 10.7759/cureus.54802

in every two postmenopausal women suffers from vulvovaginal atrophy (VVA), often called the
"genitourinary syndrome of menopause (GSM)" 
[1]
.
Recently, VVA has been termed GSM to underline the multitude of genital, urinary, and sexual symptoms
that are related to the functional and anatomical changes of vulvovaginal tissues that occur with menopause
and increasing age 
[2]
.

---

### Chunk 13/30
**Article:** Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women (2019)
**Journal:** Front Endocrinol (Lausanne)
**Section:** other | **Similarity:** 0.688

74
).Notwithstandingtheseﬁndings,HCPsmayposeverysimplequestionstofacilitateanopenconversationonurogenital
healthandtorecordthevarietyofvaginal,vulvarandurinarysymptoms.Visualvaginal,vulvarandpelvicassessmentbyHCPs
isausefulmeasurefordiagnosingVVA/GSMandassessing
responsetotreatment.Moreover,itmayhelpHCPstoidentify
womenatriskofvaginaldrynessanddyspareunia,andallow
themtoproactivelyengageinconversationsaboutsexualhealth(
75
).Figure1reportsaverysimplecheck-listtodiagnoseVVA/GSMinroutineclinicalpractice.WomenwithbreastcancerandothergynecologicalmalignanciesareatveryhighriskofVVAandassociated
symptoms.Indeed,endocrinechemotherapy,surgeryand/or
FrontiersinEndocrinology|www.frontiersin.org4August2019|Volume10|Article561

Nappietal.VaginalHealthandAging
FIGURE1|Averysimplecheck-listtodiagnoseVVA/GSMinroutineclinicalpractice.

---

### Chunk 14/30
**Article:** Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women (2019)
**Journal:** Front Endocrinol (Lausanne)
**Section:** other | **Similarity:** 0.688

  nalscoredeﬁningthedegreeofatrophyinthe
genitourinarytractbyassigningasinglescoretoeachparameter.Totalscorerangesfrom5to25,withlowerscorescorrespondingtogreaterurogenitalatrophy(
68
).VulvaHealthIndexevaluateslabia,urethra,clitoris,introitusaswellaselasticityandpainduringintercourse;totalscorerangesfrom0to24,withhigherscorescorrespondingwithgreatervulvaratrophy.IftheVulva
HealthIndexisover8orthereisscoreof3(severe)in
anycategory,vulvaratrophyissuggested(
69
).Inthemostseverecases,tissuesmaybeeasilytraumatizedandirritatedbytouchingorinsertingthespeculum(
70
).Organprolapseorhypertonicityofthepelvicﬂoorwithsecondaryvaginismmay
bealsopresent,aswellasvulvovaginalsignswhichrequirea
diﬀerentialdiagnosisbyperformingcolposcopyorcarryingout
bacteriologicalanalyses(
11
).Ingeneral,VVA/GSMistypicallyaclinicaldiagnosisandfewlaboratorytestsmaybeusedtosupporttheevidence.Amongthem,theevaluationofvaginalpHand
thevaginalmaturationindex(VMI)arethemostused(
41
).WiththeVMIitispossibletoidentifythe

---

### Chunk 15/30
**Article:** Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women (2019)
**Journal:** Front Endocrinol (Lausanne)
**Section:** other | **Similarity:** 0.686

etyfortheStudyofWomen’sSexualHealthProcessofCarefortheIdentiﬁcationofSexualConcernsandProblemsinWomen.MayoClinProc.(2019)94:84256.doi:10.1016/j.mayocp.2019.01.00941.PortmanDJ,GassML.VulvovaginalAtrophyTerminologyConsensusConferencePanel.Genitourinarysyndromeofmenopause:newterminologyforvulvovaginalatrophyfromtheInternationalSocietyfortheStudyofWomen’sSexualHealthandtheNorthAmericanMenopause
Society.Menopause.(2014)21:10638.doi:10.1097/GME.000000000000032942.GandhiJ,ChenA,DagurG,SuhY,SmithN,CaliB,etal.Genitourinarysyndromeofmenopause:anoverviewofclinical
manifestations,pathophysiology,etiology,evaluation,andmanagement.AmJObstetGynecol.(2016)215:70411.doi:10.1016/j.ajog.2016.07.04543.LewisFM.VulvalsymptomsafterthemenopauseNotallatrophy!.PostReprodHealth.(2015)21:14650.doi:10.1177/205336911560801944.Vieira-BaptistaP,DondersG,MargessonL,EdwardsL,HaefnerHK,Pérez-LópezFR.Diagnosisandmanagementofvulvodyniainpostmenopausal
women.Maturitas.(2018)108:8494.doi:10.1016/j.maturi

---

### Chunk 16/30
**Article:** Study of Vulvovaginal Atrophy and Genitourinary Syndrome of Menopause and Its Impact on the Quality of Life of Postmenopausal Women in Central India (2024)
**Journal:** Cureus
**Section:** other | **Similarity:** 0.685

ng: 
Payment/services info:
 ICMR STS 2022 STIPEND. 
Financial relationships:
 All
authors have declared that they have no financial relationships at present or within the previous three years
with any organizations that might have an interest in the submitted work. 
Other relationships:
 All authors
have declared that there are no other relationships or activities that could appear to have influenced the
submitted work.
References
1
. 
Nappi RE, Martini E, Cucinella L, et al.: 
Addressing vulvovaginal atrophy (VVA)/genitourinary syndrome of
menopause (GSM) for healthy aging in women
. Front Endocrinol (Lausanne). 2019, 10:561.
10.3389/fendo.2019.00561
2
. 
Portman DJ, Gass ML: 
Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy
from the International Society for the Study of Women's Sexual Health and the North American Menopause
Society
. Menopause. 2014, 21:1063-8. 
10.1097/GME.0000000000000329
3
.

---

### Chunk 17/30
**Article:** Study of Vulvovaginal Atrophy and Genitourinary Syndrome of Menopause and Its Impact on the Quality of Life of Postmenopausal Women in Central India (2024)
**Journal:** Cureus
**Section:** introduction | **Similarity:** 0.683

.com
Abstract
Background
Urogenital health is a necessary part of health for all women, especially in the postmenopausal age group.
We suspected that the increased incidence of vulvovaginal atrophy (VVA) had some or other effects on the
quality of life of older women. So, we aimed to study VVA/genitourinary syndrome of menopause (GSM) and
its impact on the quality of life of postmenopausal women in Central India. Despite its significant
prevalence and detrimental impact on women’s health, VVA/GSM is underdiagnosed and undertreated. In
view of the feminization of aging, VVA management is becoming increasingly crucial. This study contributes
to postmenopausal women's understanding that keeping their urogenital and sexual longevity is a critical
step toward healthy living and gender equality.

---

### Chunk 18/30
**Article:** Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women (2019)
**Journal:** Front Endocrinol (Lausanne)
**Section:** other | **Similarity:** 0.683

periencesandneeds.Maturitas.(2016)91:8190.doi:10.1016/j.maturitas.2016.06.01029.KrychmanM,GrahamS,BernickB,MirkinS,KingsbergSA.Thewomen’sEMPOWERsurvey:women’sknowledgeandawarenessoftreatmentoptionsforvulvarandvaginalatrophyremainsinadequate.JSexMed.(2017)14:42533.doi:10.1016/j.jsxm.2017.01.01130.SantoroN,KomiJ.Prevalenceandimpactofvaginalsymptomsamongpostmenopausalwomen.JSexMed.(2009)6:213342.doi:10.1111/j.1743-6109.2009.01335.x31.NappiRE,CucinellaL,MartellaS,RossiM,TiraniniL,MartiniE.Femalesexualdysfunction(FSD):prevalenceandimpactonqualityoflife(QoL).Maturitas.(2016)94:8791.doi:10.1016/j.maturitas.2016.09.01332.JanniniEA,NappiRE.Couplepause:anewparadigmintreatingsexualdysfunctionduringmenopauseandandropause.SexMedRev.(2018)6:38495.doi:10.1016/j.sxmr.2017.11.00233.BachmannG.Urogenitalageing:anoldproblemnewlyrecognized.Maturitas.(1995)22(Suppl.1):S15.doi:10.1016/0378-5122(95)00956-634.PalmaF,XholliA,CagnacciA,astheWritingGroupoftheAGATAStudy.Themostbothersomesymptomofva

---

### Chunk 19/30
**Article:** Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women (2019)
**Journal:** Front Endocrinol (Lausanne)
**Section:** other | **Similarity:** 0.683

shD,ChangK,SilverMI,etal.Associationbetweenthevaginalmicrobiota,menopausestatus,andsignsofvulvovaginalatrophy.Menopause.(2018)25:132130.doi:10.1097/GME.000000000000123664.BasaranM,KosifR,BayarU,CivelekB.Characteristicsofexternalgenitaliainpre-andpostmenopausalwomen.Climacteric.(2008)11:41621.doi:10.1080/1369713080236667065.MannellaP,PallaG,BelliniM,SimonciniT.Thefemalepelvicﬂoorthroughmidlifeandaging.Maturitas.(2013)76:2304.doi:10.1016/j.maturitas.2013.08.00866.Calleja-AgiusJ,BrincatM.P.Theurogenitalsystemandthemenopause.Climacteric.(2015)18(Suppl.1):1822.doi:10.3109/13697137.2015.107820667.NappiRE.Newattitudestosexualityinthemenopause:clinicalevaluationanddiagnosis.Climacteric.(2007)10(Suppl.2):1058.doi:10.1080/1369713070159987668.BachmannGA,NotelovitzM,KellySJ,ThompsonC,OwensA.Long-termnon-hormonaltreatmentofvaginaldryness.ClinPractSexuality.(1992)8:38.69.PanayN.Genitourinarysyndromeofthemenopausedawnofanewera?Climacteric.(2015)18(Suppl.1):137.doi:10.3109/13697137.2

---

### Chunk 20/30
**Article:** Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women (2019)
**Journal:** Front Endocrinol (Lausanne)
**Section:** other | **Similarity:** 0.679

8.doi:10.1007/s00192-014-2464-074.NappiRE,PalaciosS,BruyniksN,ParticcoM,PanayN,EVESStudyInvestigators.Theburdenofvulvovaginalatrophyonwomen’sdailyliving:implicationsonqualityoflifefromaface-to-facereal-life
survey.Menopause.(2019)26:48591.doi:10.1097/GME.000000000000126075.SimonJA,ArcherDF,KaganR,BernickB,GrahamS,ConstantineGD,etal.Visualimprovementsinvaginalmucosacorrelatewithsymptomsof
VVA:datafromadouble-blind,placebo-controlledtrial.Menopause.(2017)24:100310.doi:10.1097/GME.000000000000088076.FaubionSS,LarkinLC,StuenkelCA,BachmannGA,ChismLA,KaganR,etal.Managementofgenitourinarysyndromeofmenopauseinwomen
withorathighriskforbreastcancer:consensusrecommendationsfromTheNorthAmericanMenopauseSocietyandTheInternationalSocietyfortheStudyofWomen’sSexualHealth.Menopause.(2018)25:596608.doi:10.1097/GME.000000000000112177.SadovskyR,BassonR,KrychmanM,MoralesAM,SchoverL,WangR,etal.Cancerandsexualproblems.JSexMed.(2010)7:34973.doi:10.1111/j.1743-6109.2009.01620.x78.NappiRE,CucinellaL

---

### Chunk 21/30
**Article:** Study of Vulvovaginal Atrophy and Genitourinary Syndrome of Menopause and Its Impact on the Quality of Life of Postmenopausal Women in Central India (2024)
**Journal:** Cureus
**Section:** introduction | **Similarity:** 0.677

Received
 09/01/2023 
Review began
 10/21/2023 
Review ended
 02/13/2024 
Published
 02/24/2024
© Copyright 
2024
Ulhe et al. This is an open access article
distributed under the terms of the Creative
Commons Attribution License CC-BY 4.0.,
which permits unrestricted use, distribution,
and reproduction in any medium, provided
the original author and source are credited.
Study of Vulvovaginal Atrophy and Genitourinary
Syndrome of Menopause and Its Impact on the
Quality of Life of Postmenopausal Women in
Central India
Samiksha 
C. Ulhe 
, 
Neema Acharya 
, 
Aarav Vats 
, 
Awantika singh 
1.
 Department of Obstetrics and Gynecology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher
Education and Research, Wardha, IND
Corresponding author: 
Samiksha 
C. Ulhe, 
samiulhe17@gmail.com
Abstract
Background
Urogenital health is a necessary part of health for all women, especially in the postmenopausal age group.

---

### Chunk 22/30
**Article:** Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women (2019)
**Journal:** Front Endocrinol (Lausanne)
**Section:** other | **Similarity:** 0.676

1177/205336911560801944.Vieira-BaptistaP,DondersG,MargessonL,EdwardsL,HaefnerHK,Pérez-LópezFR.Diagnosisandmanagementofvulvodyniainpostmenopausal
women.Maturitas.(2018)108:8494.doi:10.1016/j.maturitas.2017.11.00345.JohnstonSL.Pelvicﬂoordysfunctioninmidlifewomen.Climacteric.(2019)11:17.doi:10.1080/13697137.2019.156840246.ShifrenJL,ZincavageR,ChoEL,MagnavitaA,PortmanDJ,KrychmanML,etal.Women’sexperienceofvulvovaginal
symptomsassociatedwithmenopause.Menopause.(2019)26:3419.doi:10.1097/GME.000000000000127547.SarrelPM.Sexualityandmenopause.ObstetGynecol.(1990)75:26S−35S.doi:10.1097/00006250-199004001-0000648.LeiblumS,BachmannG,KemmannE,ColburnD,SwartzmanL.Vaginalatrophyinthepostmenopausalwoman.TheimportanceofsexualactivityandhormonesJAMA.(1983)249:21958.doi:10.1001/jama.1983.0333040004102249.SimonJA,GoldsteinI,KimNN,DavisSR,Kellogg-SpadtS,LowensteinL,etal.Theroleofandrogensinthetreatmentofgenitourinary
syndromeofmenopause(GSM):InternationalSocietyforthe
StudyofWomen’sSexualH

---

### Chunk 23/30
**Article:** Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women (2019)
**Journal:** Front Endocrinol (Lausanne)
**Section:** other | **Similarity:** 0.676

,ChenBH,HernandezDG,SingletonAB,FerrucciL,etal.Menopauseacceleratesbiologicalaging.ProcNatlAcadSciUSA.(2016)113:932732.doi:10.1073/pnas.16045581137.PalaciosS,Castelo-BrancoC,CurrieH,MijatovicV,NappiRE,SimonJ,etal.Updateonmanagementofgenitourinarysyndrome
ofmenopause:apracticalguide.Maturitas.(2015)82:30813.doi:10.1016/j.maturitas.2015.07.0208.NappiRE,CucinellaL.Advancesinpharmacotherapyfortreatingfemalesexualdysfunction.ExpertOpinPharmacother.(2015)16:87587.doi:10.1517/14656566.2015.10207919.FaubionSS,SoodR,KapoorE.Genitourinarysyndromeofmenopause:managementstrategiesfortheclinician.MayoClinProc.(2017)92:18429.doi:10.1016/j.mayocp.2017.08.01910.ShifrenJL.Genito-urinarysyndromeofmenopause.ClinObstetGynecol.(2018)61:50816.doi:10.1097/GRF.000000000000038011.NaumovaI,Castelo-BrancoC.Currenttreatmentoptionsforpostmenopausalvaginalatrophy.IntJWomensHealth.(2018)10:38795.doi:10.2147/IJWH.S15891312.DondersGGG,RubanK,BellenG,GrincevicieneS.Pharmacotherapyforthetreatmentofvaginalatro

---

### Chunk 24/30
**Article:** Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women (2019)
**Journal:** Front Endocrinol (Lausanne)
**Section:** introduction | **Similarity:** 0.676

t,butrecentobservationsbringabouttheideathatmenopauseacceleratesbiologicalaging,especiallywhenreproductivefailureoccursprematurely(
6
).Thepresentnarrativereviewpointstotheimportanceofaddressingthechronicconditionofvulvovaginalatrophy
(VVA)/genitourinarysyndromeofmenopause(GSM)inthe
contextofpromotingurogenitalandsexuallongevityinwomenatmidlifeandbeyond.Itmerelyreﬂectstheexpertopinionof
theauthorsbyanalyzingtheamountofavailableevidence(19902019)inthiscomplexﬁeldofresearch.TherapeuticstrategiestoeﬀectivelymanagesexualsymptomsassociatedwithVVA/GSM
havebeenreviewedextensivelyelsewhere(
7

12
)and,inhere,theywillbediscussedbrieﬂytoservethescopeofpreventing
severeVVA/GSMinelderlywomen.

---

### Chunk 25/30
**Article:** Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women (2019)
**Journal:** Front Endocrinol (Lausanne)
**Section:** other | **Similarity:** 0.675

REVIEWpublished:21August2019doi:10.3389/fendo.2019.00561
FrontiersinEndocrinology|www.frontiersin.org1August2019|Volume10|Article561
Editedby:SandroLaVignera,UniversityofCatania,ItalyReviewedby:ErikaLimoncin,UniversityofRomeTorVergata,ItalyRobertaVenturella,UniversitàdegliStudiMagnaGræciadiCatanzaro,Italy*Correspondence:RossellaE.Nappirenappi@tin.itSpecialtysection:ThisarticlewassubmittedtoEndocrinologyofAging,asectionofthejournalFrontiersinEndocrinologyReceived:22May2019Accepted:31July2019Published:21August2019Citation:NappiRE,MartiniE,CucinellaL,MartellaS,TiraniniL,InzoliA,BrambillaE,BosoniD,CassaniCandGardellaB(2019)AddressingVulvovaginalAtrophy(VVA)/GenitourinarySyndromeofMenopause(GSM)forHealthyAginginWomen.Front.Endocrinol.10:561.doi:10.3389/fendo.2019.00561AddressingVulvovaginalAtrophy
(VVA)/GenitourinarySyndromeof
Menopause(GSM)forHealthyAging
inWomen
RossellaE.Nappi1,2*,EllisMartini1,LauraCucinella1,2,SilviaMartella1,2,LaraTiranini1,2,AlessandraInzoli1,2,EmanuelaBrambilla1,2

---

### Chunk 26/30
**Article:** Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women (2019)
**Journal:** Front Endocrinol (Lausanne)
**Section:** other | **Similarity:** 0.674

isHA,HanL,DornerAJ,ApseloﬀG,etal.Astudyof17beta-estradiol-regulatedgenesinthevaginaofpostmenopausalwomenwithvaginalatrophy.Maturitas.(2007)58:36676.doi:10.1016/j.maturitas.2007.09.00953.SturdeeDW,PanayN,InternationalMenopauseSocietyWritingGroup.Recommendationsforthemanagementofpostmenopausalvaginalatrophy.Climacteric.(2010)13:50922.doi:10.3109/13697137.2010.52287554.ForsbergJG.Amorphologist’sapproachtothevaginaage-relatedchangesandestrogensensitivity.Maturitas.(1995)22:S7S15.doi:10.1016/0378-5122(95)00957-455.CaillouetteJC,SharpCFJr,ZimmermanGJ,RoyS.VaginalpHasamarkerforbacterialpathogensandmenopausalstatus.AmJObstetGynecol.(1997)176:12705.doi:10.1016/S0002-9378(97)70345-456.RobinsonD,CardozoLD.Theroleofestrogensinfemalelowerurinarytractdysfunction.Urology.(2003)62:4551.doi:10.1016/S0090-4295(03)00676-957.Castelo-BrancoC,CanceloMJ,VilleroJ,NohalesF,JuliáMD.Managementofpost-menopausalvaginalatrophyandatrophicvaginitis.Maturitas.(2005)52(Suppl.1):S4652.doi:10.1016/j.ma

---

### Chunk 27/30
**Article:** Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women (2019)
**Journal:** Front Endocrinol (Lausanne)
**Section:** other | **Similarity:** 0.673

ngesoftheurinarysystem(reducedurethralclosurepressure,reducedsensorythresholdinthebladder,and,insomecases,increasedriskofrUTIs)maybeobservedasaconsequenceof
thethinningoftheurinaryepitheliumandweakeningofthe
surroundingtissue(
53
).KEY-ELEMENTSOFVVA/GSMDIAGNOSIS
Clinicalinterviewsandratingscalestoscorethemost
bothersomesymptoms(MBS)(Table1)areusefulinstrumentstomeasuresubjectivesymptomsandtoidentifyriskfactors
forVVA/GSM.Objectivediagnosisisconﬁrmedbyanaccurate
pelvicexamination,includinggentleinspectionofthevulva,vestibule,vagina,andurethrainordertorecognizethesignsofVVA/GSM(Table1)whichcanberatedonvalidatedscales(
67
).TheVaginalHealthIndexScoreisaclinicaltoolthat,byevaluating5parameters(vaginalelasticity,vaginalsecretions,pH,epithelialmucousmembrane,vaginalhydration),allows
toobtainaﬁnalscoredeﬁningthedegreeofatrophyinthe
genitourinarytractbyassigningasinglescoretoeachparameter.Totalscorerangesfrom5to25,withlowerscorescorrespondingtogreaterurogenitalatrophy(
68
).VulvaHealthIn

---

### Chunk 28/30
**Article:** Study of Vulvovaginal Atrophy and Genitourinary Syndrome of Menopause and Its Impact on the Quality of Life of Postmenopausal Women in Central India (2024)
**Journal:** Cureus
**Section:** other | **Similarity:** 0.673

cation, communication, research, and care of sexual and urogenital problems in postmenopausal
females, led to the selection of GSM. The definition of the syndrome describes various clinical signs and
symptoms (genitourinary) corresponding to one another that do not have to be all present and related to
solitary identifiable etiology but occur in a specific circumstance (menopause).
The definition of GSM is "a collection of symptoms and signs associated with a reduction in estrogen and
other female gonad hormones that involves alterations to the vestibule, clitoris, labia majora, labia minora,
vagina, urethra, and urinary bladder" 
[3]
. Genitourinary symptoms of burning, irritation, and dryness,
dysuria, urgency, incontinence, nocturia and repeated infections of the urinary tract and sexual symptoms
of pain or discomfort, lack of lubrication, and postcoital bleeding are all possible indications of the syndrome
[2]
.

---

### Chunk 29/30
**Article:** Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women (2019)
**Journal:** Front Endocrinol (Lausanne)
**Section:** other | **Similarity:** 0.670

ey:attitudesandbehaviorsofphysicianstowardvulvarandvaginalatrophy(VVA)treatmentinwomenincluding
thosewithbreastcancerhistory.Menopause.(2019)26:12431.doi:10.1097/GME.000000000000119438.KingsbergSA,SchaﬃrJ,FaughtBM,PinkertonJV,ParishSJ,IglesiaCB,etal.Femalesexualhealth:barrierstooptimaloutcomesandaroadmap
forimprovedpatient-cliniciancommunications.JWomensHealth.(2019)28:43243.doi:10.1089/jwh.2018.735239.Al-AzzawiF,BitzerJ,BrandenburgU,Castelo-BrancoC,GraziottinA,KenemansP,etal.Therapeuticoptionsforpostmenopausal
femalesexualdysfunction.Climacteric.(2010)13:10320.doi:10.3109/13697130903437615
FrontiersinEndocrinology|www.frontiersin.org8August2019|Volume10|Article561

Nappietal.VaginalHealthandAging
40.ParishSJ,HahnSR,GoldsteinSW,GiraldiA,KingsbergSA,LarkinL,etal.TheInternationalSocietyfortheStudyofWomen’sSexualHealthProcessofCarefortheIdentiﬁcationofSexualConcernsandProblemsinWomen.MayoClinProc.(2019)94:84256.doi:10.1016/j.mayocp.2019.01.00941.PortmanDJ,GassML.Vulvovaginal

---

### Chunk 30/30
**Article:** Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women (2019)
**Journal:** Front Endocrinol (Lausanne)
**Section:** other | **Similarity:** 0.669

lwomen,progressiveandchronicVVAsymptomshaveastrongimpactonsexualfunctionandqualityoflife.Thenewdeﬁnitionofgenitourinarysyndromeofmenopause(GSM)comprisesgenitalsymptoms(dryness,burning,itching,irritation,bleeding),sexualsymptoms(dyspareuniaandothersexualdysfunctions)andurinarysymptoms(dysuria,frequency,urgency,recurrenturinaryinfections).Manyvariables(age,sexualactivityandpartnershipstatus)inﬂuencetheclinicalimpactVVA/GSMsymptomsandattitudesofelderlywomentoconsultforreceivingeffectivetreatments.Psychosocialfactorsplayacriticalroleinsexualfunctioning,buttheintegrityoftheurogenitalsystemisaswellimportantaffectingmanydomainsofpostmenopausalwomen’shealth,includingsexualfunction.SeveralinternationalsurveyshaveextensivelydocumentedtheneedtoimproveVVA/GSMmanagementbecauseofthestrongimpactonwomen’sdailylifeandoncouple’sintimacy.Healthcareproviders(HCPs)needtobeproactiveintheearlyrecognitionofVVA/GSMinordertopreserveurogenitalandsexuallongevity,byusinghormonalandnon-hormonalstrategies.

---

